Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Nov 19;30(49):7097-104.
doi: 10.1016/j.vaccine.2012.09.040. Epub 2012 Sep 28.

The potential economic value of a human norovirus vaccine for the United States

Sarah M Bartsch  1 , Benjamin A Lopman, Aron J Hall, Umesh D Parashar, Bruce Y Lee
Affiliations

The potential economic value of a human norovirus vaccine for the United States

Sarah M Bartsch et al. Vaccine. .

Abstract

Vaccines against human norovirus are currently under development. We developed a simulation model to determine their potential economic value. Vaccination prevented 100-6125 norovirus gastroenteritis cases per 10,000 vaccinees. Low vaccine cost (≤$50) garnered cost-savings and a more expensive vaccine led to costs per case averted comparable to other vaccines. In the US, vaccination could avert approximately 1.0-2.2 million cases (efficacy 50%, 12 month duration), costing an additional $400 million to $1.0 billion, but could save ≤$2.1 billion (48 month duration). Human norovirus vaccination can offer economic value while averting clinical outcomes, depending on price, efficacy, and protection duration.

PubMed Disclaimer

Conflict of interest statement

The authors are not aware of any significant conflicts of interest.

Figures

Figure 1
Figure 1
General Flow of Individuals in the Markov Model
Figure 2
Figure 2
Cost per Norovirus Gastroenteritis Episode Averted by Vaccination A) for a Vaccine Efficacy of 50%, Cost $25; B) for a Vaccine Efficacy of 50%, Cost $50; C) for a Vaccine Efficacy of 50%, Cost $75; D) for a Vaccine Efficacy of 75%, Cost $25; E) for a Vaccine Efficacy of 75%, Cost $50; F) for a Vaccine Efficacy of 75%, Cost $75
See this image and copyright information in PMC

References

    1. Tam CC, Rodrigues LC, Viviani L, Dodds JP, Evans MR, Hunter PR, et al. Longitudinal study of infectious intestinal disease in the UK (IID2 study): incidence in the community and presenting to general practice. Gut. 2012;61(1):69–77. - PMC - PubMed
    1. Hall AJ, Rosenthal M, Gregoricus N, Greene SA, Ferguson J, Henao OL, et al. Incidence of acute gastroenteritis and role of norovirus, Georgia, USA, 2004–2005. Emerging Infectious Diseases. 2011;17(8):1381–1388. - PMC - PubMed
    1. Phillips G, Tam CC, Conti S, Rodriguez LC, Brow D, Iturriza-Gomara M, et al. Community incidence of norovirus-associated infectious intestinal disease in England: improved estimates using viral load for norovirus diagnosis. American Journal of Epidemiology. 2010;171(9):1014–1022. - PubMed
    1. Patel MM, Hall AJ, Vinje J, Parashar UD. Noroviruses: a comprehensive review. J Clin Virol. 2009 Jan;44(1):1–8. - PubMed
    1. Hall AJ, Vinje J, Lopman B, Park GW, Yen C, Gregoricus N, et al. Updated norovirus outbreak management and disease prevention guidlines. Morbidity and Mortality Weekly Reports: Recommendations and Reports. 2011;60(3) - PubMed

Publication types

MeSH terms